This article provides commentary on AI regulation, discussing expert opinions and policy implications without announcing any new developments or concrete events.
This collaboration signals a major industry shift towards AI-driven clinical development. By pooling data and leveraging AI, AstraZeneca and its partners can significantly shorten drug development timelines, reduce failure rates, and gain a competitive edge in bringing new therapies to market faster.
Evinova, an AstraZeneca business, partners with Astellas and Bristol Myers Squibb.
The collaboration will leverage Evinova's AI-native platform to accelerate clinical trials.
Partners will share operational data to enable AI-powered benchmarks and recommendations.
This collaboration highlights the growing importance of AI in drug development, a trend APAC pharma companies must monitor. With increasing clinical trial activity in markets like China, India, and Japan, adopting AI platforms can significantly accelerate drug approvals and market access, enhancing regional competitiveness and patient outcomes.
The collaboration will leverage Evinova's AI-native platform to accelerate clinical trials.
Partners will share operational data to enable AI-powered benchmarks and recommendations.
Sign in to save notes on signals.
Sign In